ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,909.03
-1.11%
Dow Jones
42,528.36
-0.42%
US Dollar vs MXN
20.33749
0.03%
Brent Oil
77.075
0.02%
Bitcoin
96,473.83
-0.44%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) Noticias

CALT

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CALT
FechaHoraFuenteTítuloSímboloCompañía
23/09/202415:44Edgar (US Regulatory)Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]NASDAQ:CALTCalliditas Therapeutics AB
16/09/202408:46PR Newswire (US)Delisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmNASDAQ:CALTCalliditas Therapeutics AB
03/09/202406:13PR Newswire (US)Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
03/09/202405:33PR Newswire (US)Calliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiNASDAQ:CALTCalliditas Therapeutics AB
13/08/202400:25PR Newswire (US)Calliditas Interim Report January to June 2024NASDAQ:CALTCalliditas Therapeutics AB
05/08/202400:26PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - June 2024NASDAQ:CALTCalliditas Therapeutics AB
01/08/202408:00GlobeNewswire Inc.Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership ConferenceNASDAQ:CALTCalliditas Therapeutics AB
31/07/202407:23PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsNASDAQ:CALTCalliditas Therapeutics AB
26/07/202415:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
26/07/202410:23PR Newswire (US)Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyNASDAQ:CALTCalliditas Therapeutics AB
26/07/202401:29PR Newswire (US)Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisNASDAQ:CALTCalliditas Therapeutics AB
04/07/202402:44PR Newswire (US)Launch of Phase 3 clinical trial with Nefecon in JapanNASDAQ:CALTCalliditas Therapeutics AB
18/06/202405:25PR Newswire (US)Calliditas provides setanaxib patent updateNASDAQ:CALTCalliditas Therapeutics AB
17/06/202411:01PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
30/05/202413:20PR Newswire (US)Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyNASDAQ:CALTCalliditas Therapeutics AB
28/05/202407:46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202407:09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
28/05/202402:17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
23/05/202400:55PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
16/05/202401:45PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
15/05/202407:30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202406:36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
14/05/202406:52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
06/05/202401:16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
24/04/202412:35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202402:30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
18/04/202406:13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
09/04/202406:24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
08/04/202407:38PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
08/04/202402:24PR Newswire (US)Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentNASDAQ:CALTCalliditas Therapeutics AB
 Showing the most relevant articles for your search:NASDAQ:CALT

Su Consulta Reciente

USI
USTECH100
US Tech 100
COIN
SOLUSD
Solana
NASDAQ
MSFT
Microsoft
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
NYSE
VZ
Verizon Communications
COIN
ETHUSD
Ethereum
CCOM
OILBRENT
Brent Oil
NYSE
XOM
Exxon Mobil
NYSE
DIS
Walt Disney
CCOM
US500
US 500
NYSE
CVX
Chevron
FX
USDMXN
US Dollar vs MXN
NYSE
NKE
Nike
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados